Login | Register

Extended Use Of Zytiga Approved By FDA For Late-Stage Prostate Cancer

Today the U.S. Food and Drug Administration (FDA) lengthened the approved use of Zytiga (abiraterone acetate) as treatment for men with late-stage, castration-resistant prostate cancer (metastatic) before undergoing chemotherapy. First approved in 2011, Zytiga is used in patients whose prostate cancer developed further after treatment with docetaxel, a chemotherapy drug...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *